Market Place
Sourcing Support
Supriya Lifescience expands global footprint with Esketamine HCL
11 Dec 2024 //
PRESS RELEASE
J&J Showcases Neuropsychiatry Portfolio At Psych Congress
24 Oct 2024 //
PR NEWSWIRE
J&J seeks expanded approval for antidepressant Spravato
22 Jul 2024 //
PRESS RELEASE
OptiMed Introduces New Service For Treatment-Resistant Depression
12 Jun 2024 //
ACCESSWIRE
Johnson & Johnson 1Q Results
20 May 2024 //
CONTRACT PHARMA
Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR
08 Oct 2023 //
GLOBENEWSWIRE
FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride
25 Apr 2023 //
FDA
China Approves Sales of Janssen’s Antidepressant
22 Apr 2023 //
YICAIGLOBAL
Nasal spray could help prevent depression relapse
28 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
24 Nov 2022 //
CLINICALTRIALSARENA
J&J builds case for Spravato in tough-to-treat depression
24 Nov 2022 //
FIERCEPHARMA
SPRAVATO data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy
23 Nov 2022 //
BUSINESSWIRE
Stigma in drug research holding back new therapies
10 Oct 2022 //
ECONOMIC TIMES
NICE`s rebuff of J&J depression nasal spray under scrutiny
09 Sep 2022 //
FIERCEPHARMA
Janssen`s Chemical Spravato (Esketamine HCl) Receives Approval in the U.S.
03 Jan 2022 //
FDA
NLS Initiates Ph2 Trial for Quilience in Narcolepsy
14 Sep 2021 //
ACESSWIRE
PharmaTher Provides Research and Development Update and Milestones for 2021
10 Jun 2021 //
GLOBENEWSWIRE
AJP Publishes International Ketamine and Esketamine Treatment Guidance
09 Jun 2021 //
PRNEWSWIRE
Janssen`s esketamine nasal spray gets Europe approval for new indication
09 Feb 2021 //
PHARMAFILE
Janssen Receives Positive CHMP Opinion for SPRAVATO®
11 Dec 2020 //
BUSINESSWIRE
Janssen Receives Positive CHMP Opinion for SPRAVATO®?
11 Dec 2020 //
BUSINESSWIRE
NICE knocks back Janssens Spravato nasal spray for the second time in treatment
03 Sep 2020 //
PHARMAFILE
Champignon to Begin Offering Esketamine Treatment for Adults With MSD
27 Aug 2020 //
GLOBENEWSWIRE
Johnson & Johnson Spray Approved for Treating Suicidal People
03 Aug 2020 //
BNNBLOOMBERG
(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients
22 Jul 2020 //
MARKETS
J&J`s depression spray Spravato fails cost-effectiveness review
29 Jan 2020 //
FIERCE PHARMA
J&J gets EU approval for depression nasal spray Spravato
21 Dec 2019 //
PM LIVE
Janssen Receives Positive CHMP Opinion for Spravato
18 Dec 2019 //
PRESS RELEASE
Janssen Submits Supplemental NDA to U.S. FDA for SPRAVATO® (esketamine)
03 Oct 2019 //
PR NEWSWIRE
J&J scores Spravato trial win in high-risk depression
10 Sep 2019 //
FIERCE PHARMA
Get as much Spravato as you can, Trump orders VA while suggesting J&J
23 Aug 2019 //
ENDPTS
J&J depression drug Spravato gets half-hearted backing from VA doctors
24 Jun 2019 //
FIERCE PHARMA
Cost-effectiveness watchdogs skewer J&J`s depression spray Spravato
22 Jun 2019 //
FIERCE PHARMA
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
12 Jun 2019 //
KHN
Stung by critics, J&J says antidepressant Spravato saves money
23 May 2019 //
PMLIVE
New data highlights value of Janssen’s Spravato
23 May 2019 //
PHARMA TIMES
Cost watchdogs take issue with J&J`s Spravato price
11 May 2019 //
FIERCE PHARMA
Esketamine and psychedelics will require restructuring mental health care visits
04 Apr 2019 //
STATNEWS
The FDA just approved this groundbreaking antidepressant nasal spray
08 Mar 2019 //
SLASHGEAR
Addiction specialist expresses concern after FDA approves esketamine
07 Mar 2019 //
IN- PHARMATECHNOLOGIST
J&J’s Spravato breaks depression drought at FDA
06 Mar 2019 //
PMLIVE
So you just got a BTD for your top drug? Don’t be surprised
22 Feb 2019 //
ENDPTS
Johnson & Johnson`s nasal spray for depression wins FDA panel backing
14 Feb 2019 //
REUTERS
Depression Therapy With Party-Drug Roots Faces FDA Panel Review
09 Feb 2019 //
BLOOMBERG
J&J’s Esketamine for Depression Faces an FDA Panel Next Week
08 Feb 2019 //
BIOSPACE
Janssen Submits EMA Application for Esketamine Nasal Spray
11 Oct 2018 //
BUSINESSWIRE
Janssen files nasal spray for depression
10 Oct 2018 //
PHARMA TIMES
Janssen Announces Results of Esketamine Nasal Spray
21 Sep 2018 //
PR NEWSWIRE
J&J racks up fresh +ve pivotal data for esketamine amidst safety concerns
01 Jun 2018 //
ENDPTS
Aspen Moves Production to New $79 Million South Africa Plant
08 May 2018 //
BLOOMBERG
J&J preps for esketamine filing in resistant depression, despite a missed trial
07 May 2018 //
FIERCE BIOTECH
Nasal spray of party drug shows promise as fast-acting antidepressant
20 Apr 2018 //
WASHINGTONPOST
0-for-3 in PhIII: Auris’ late-stage changeup fails to save tinnitus drug
13 Mar 2018 //
ENDPTS
